Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14785651 | 0.87 | KMT2A (0.43) | KMT2AMEN1KIF11PARP10PARP3 | |
| SCHEMBL10081937 | 0.82 | KMT2A (0.58) | KMT2AMEN1KIF11PARP10PARP3 | |
| SCHEMBL15797873 | 0.80 | KMT2A (0.41) | KMT2AMEN1KIF11PARP10PARP3 | |
| SCHEMBL6284986 | 0.78 | KMT2A (0.64) | KMT2AMEN1KIF11PARP10MAPT | |
| SCHEMBL15798252 | 0.78 | MAPK1 (0.51) | KMT2AMEN1MAPTKDM4ETP53 | |
| SCHEMBL28636841 | 0.77 | PARP10 (0.68) | KMT2AMEN1KIF11PARP10PARP3 | |
| SCHEMBL1883642 | 0.76 | KMT2A (0.47) | KMT2AMEN1KIF11PARP10PARP3 | |
| SCHEMBL3964510 | 0.76 | F3 (0.50) | KMT2APARP10MAPTALDH1A1GSK3B | |
| SCHEMBL14480241 | 0.75 | NNMT (0.37) | KMT2AMEN1PARP10PARP3MAPT | |
| SCHEMBL11375698 | 0.74 | KMT2A (0.45) | KMT2AMEN1KIF11PARP10PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2015-11-05 | — | — | US | claimed |
| EP-2928860-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2015-10-14 | — | — | EP | claimed |
| WO-2014090731-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2014-06-19 | — | — | WO | claimed |
| EP-2888247-B1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9388171-B2 | Serine/threonine kinase inhibitors | GENETECH, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2015-11-05 | — | — | US | disclosed |
| EP-2928860-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2015-10-14 | — | — | EP | disclosed |
| EP-2888247-A1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE!DISEASES | Array Biopharma, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014090731-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2014-06-19 | — | — | WO | disclosed |
| US-20140066453-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014036015-A1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE|DISEASES | ARRAY BIOPHARMA INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-8497271-B2 | Modulators of G protein-coupled receptor 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2486030-B1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2486030-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | KMT2A 1874/4885MEN1 4143/4885KIF11 2813/4885 |
| US-20140066453-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K20 | KMT2A 1752/4885MEN1 1200/4885KIF11 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.